A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor. Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected. The main questions it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection 2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection

NCT Number	NCT06883539
Lead Sponsor	LaunXP Biomedical Co., Ltd. Collaborators: Efficient Pharma Management Corp.
Conditions	Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Solid Tumour, Solid Tumors Refractory to Standard Therapy, HCC - Hepatocellular Carcinoma, RCC, Renal Cell Cancer +1 more
Enrollment	24 participants
Start Date	2024-12-31
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-03-19